ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial Posted on September 18, 2018 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Submission - FINAL